LONDON, March 5 /PRNewswire/ -- The demand for a reliable, non-invasive, efficient and cost-effective technology that improves patients' lifestyles is boosting interest in bone growth and spinal fusion stimulators in Europe. The market is however still small, as clinicians have felt that the technology needs to be better proved. This situation is changing though, as companies introduce innovative products with clinical studies and research papers to substantiate the efficacy of their offerings.
New analysis from Frost & Sullivan (http://www.medicaldevices.frost.com), European Bone Growth and Spinal Fusion Stimulators Markets, finds that the markets earned revenues of $73.5 million in 2007 and estimates this to reach $118.0 million by 2014.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the European bone growth and spinal fusion stimulators markets, then send an e-mail to Katja Feick, Corporate Communications, at email@example.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by e-mail.
"An increasing number of scientific research studies support these technologies," notes a Frost & Sullivan analyst. "Each year, manufacturers and independent researchers are publishing more papers, describing in greater detail how stimulation has beneficial effects and which types of patients can best benefit from this treatment."
There is still a great deal of debate among orthopaedicians about what dosage of stimulation is optimal for a given patient with a given condition. However, most of them now agree that the technology is able to produce good results in most selected patients.
Reimbursement still remains an issue for the market, but some hospitals are now including bone growth stimulation in their budgets. Although used primarily for treating worst-case failures, they are gradually gaining acceptance as an alternative to non-union surgery.
"This technology has met with much resistance in Europe, but as clinical experience is gained, bone growth stimulation will be regarded as a good option at the surgeon's disposal in the future," states the analyst. "Patients tend to get coverage from private or public insurance for other treatments, yet for bone and spinal fusion stimulators no coverage is offered, giving patients the impression that one treatment is better or more accepted than the other."
European Bone Growth and Spinal Fusion Stimulators Markets is part of the Medical Devices Growth Partnership Service programme, which also includes research in the following markets: European Markets for Bone Grafts and Bone Cements and Issues and Trends in Infection Control Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.frost.com.
European Bone Growth and Spinal Fusion Stimulators Markets
Contact: Katja Feick Corporate Communications P: +49 (0) 69 7703343 E: firstname.lastname@example.org http://www.frost.com
|SOURCE Frost & Sullivan|
Copyright©2009 PR Newswire.
All rights reserved